Agios Pharmaceuticals (AGIO) Cash from Financing Activities (2012 - 2026)

Agios Pharmaceuticals has reported Cash from Financing Activities for 15 years, with the latest figure at $2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 28.35% year-over-year to $2.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (down 10.41% YoY), and the FY2025 full-year result was $8.7 million, down 39.93% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $2.1 million, down from $2.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $5.9 million in Q1 2024, with the low at -$67000.0 in Q2 2022.
• Historically, Cash from Financing Activities has averaged $1.9 million across 5 years, with a median of $1.6 million in 2025.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 3750.0% — and 2025, when it plunged 94.09%.
• Agios Pharmaceuticals' Cash from Financing Activities stood at $22000.0 in 2022, then surged by 3750.0% to $847000.0 in 2023, then jumped by 471.66% to $4.8 million in 2024, then sank by 47.19% to $2.6 million in 2025, then decreased by 18.73% to $2.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $2.1 million (Q1 2026), $2.6 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.